Analysts Expect Novadaq Technologies Inc (NVDQ) to Announce -$0.23 EPS
Equities research analysts forecast that Novadaq Technologies Inc (NASDAQ:NVDQ) (TSE:NDQ) will post earnings of ($0.23) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Novadaq Technologies’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.25). Novadaq Technologies posted earnings per share of ($0.29) in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.7%. The business is scheduled to issue its next earnings results on Wednesday, July 26th.
On average, analysts expect that Novadaq Technologies will report full-year earnings of ($0.86) per share for the current financial year, with EPS estimates ranging from ($0.94) to ($0.77). For the next financial year, analysts anticipate that the firm will report earnings of ($0.71) per share, with EPS estimates ranging from ($0.94) to ($0.49). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Novadaq Technologies.
Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.03. The company had revenue of $21.08 million during the quarter, compared to analysts’ expectations of $20.12 million. Novadaq Technologies had a negative net margin of 71.97% and a negative return on equity of 49.93%.
NVDQ has been the topic of several recent analyst reports. First Analysis lowered Novadaq Technologies from an “overweight” rating to an “equal weight” rating in a report on Tuesday, June 20th. Royal Bank Of Canada lowered Novadaq Technologies from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $12.00 to $11.75 in a report on Thursday, July 13th. Canaccord Genuity reissued a “buy” rating and issued a $10.00 target price on shares of Novadaq Technologies in a report on Monday, June 19th. JMP Securities reissued a “market perform” rating on shares of Novadaq Technologies in a report on Thursday, July 13th. Finally, Scotiabank reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Novadaq Technologies in a report on Thursday, May 4th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $11.63.
Large investors have recently made changes to their positions in the stock. Chicago Capital Management LLC purchased a new stake in shares of Novadaq Technologies during the second quarter worth approximately $406,000. Virtu Financial LLC purchased a new stake in shares of Novadaq Technologies during the second quarter worth approximately $157,000. Clearbridge Investments LLC increased its stake in shares of Novadaq Technologies by 0.4% in the first quarter. Clearbridge Investments LLC now owns 2,554,843 shares of the medical research company’s stock worth $19,902,000 after buying an additional 9,371 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Novadaq Technologies by 31.6% in the first quarter. Bank of America Corp DE now owns 832,203 shares of the medical research company’s stock worth $6,484,000 after buying an additional 199,936 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in shares of Novadaq Technologies during the first quarter worth approximately $410,000. Hedge funds and other institutional investors own 88.26% of the company’s stock.
Novadaq Technologies (NVDQ) traded up 0.09% during mid-day trading on Tuesday, hitting $11.73. The stock had a trading volume of 505,409 shares. The firm has a 50-day moving average of $8.20 and a 200-day moving average of $7.47. Novadaq Technologies has a 52-week low of $5.84 and a 52-week high of $12.74. The stock’s market cap is $678.02 million.
Novadaq Technologies Company Profile
NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.